Federated Hermes
TYRA icon

Federated Hermes’s Tyra Biosciences TYRA Stock Holding History

Federated Hermes’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8K Sell
369
-345
-48% -$11.4K ﹤0.01% 1834
2026
Q1 		$27.3K Sell
714
-583
-45% -$18.9K ﹤0.01% 1748
2025
Q4 		$34.1K Sell
1,297
-858
-40% -$15.8K ﹤0.01% 1681
2025
Q3 		$30.1K Buy
2,155
+1,841
+586% +$21K ﹤0.01% 1756
2025
Q2 		$3K Sell
314
-161
-34% -$1.53K ﹤0.01% 1928
2025
Q1 		$4.42K Sell
475
-553
-54% -$7.16K ﹤0.01% 1889
2024
Q4 		$14.3K Buy
1,028
+98
+11% +$1.78K ﹤0.01% 1803
2024
Q3 		$21.9K Buy
930
+364
+64% +$7.64K ﹤0.01% 1744
2024
Q2 		$9.05K Sell
566
-147
-21% -$2.53K ﹤0.01% 1790
2024
Q1 		$11.7K Sell
713
-1,357
-66% -$22.3K ﹤0.01% 1763
2023
Q4 		$28.7K Buy
2,070
+1,916
+1,244% +$24.8K ﹤0.01% 1711
2023
Q3 		$2.12K Sell
154
-2,911
-95% -$43.2K ﹤0.01% 1966
2023
Q2 		$52.2K Buy
3,065
+3,011
+5,576% +$43.7K ﹤0.01% 1664
2023
Q1 		$868 Buy
+54
New +$642 ﹤0.01% 2049

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Federated Hermes's TYRA Position: Q2 2026 in Review

Federated Hermes reduced its Tyra Biosciences (TYRA) stake by 48% in Q2 2026, selling an estimated $11.4K and leaving 369 shares worth $11.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

Federated Hermes first reported a position in TYRA in Q1 2023 and has held it in 14 quarters since. The position peaked at $52.2K in Q2 2023. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Federated Hermes held 369 shares of Tyra Biosciences worth $11.8K as of Q2 2026.
  • Federated Hermes sold 345 Tyra Biosciences shares in Q2 2026, an estimated $11.4K.
  • Tyra Biosciences made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1834 holding.
  • Federated Hermes first reported a position in Tyra Biosciences in Q1 2023 and has held it in 14 quarters since.
  • Federated Hermes's Tyra Biosciences position peaked at $52.2K in Q2 2023.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.